Rapid Micro Biosystems earnings missed by $0.03, revenue fell short of estimates

Rapid Micro Biosystems (RPID) reported Q3 EPS of -$0.23, missing estimates by $0.03, with revenue at $9.53M, below the $9.8M consensus. The stock closed at $0.65, down 61.02% over 3 months and 82.26% over 12 months. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 16, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 5:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RPID
Bearish
high confidence
Mentioned
$RPID
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RPIDBearishMed
01

Why it matters

A simultaneous EPS and revenue miss typically pressures short-term sentiment and can lead to estimate cuts, especially for small-cap, loss-making issuers.

02

Market read

Traders can use the reported miss versus consensus to reassess near-term expectations and positioning around subsequent earnings.

03

What to watch

The article does not include guidance, cash burn, or backlog details, which could materially change the earnings quality assessment.

Relevance 8/10Novelty 8/10Timing: reported third-quarter results (after the close, per article)

Background

The piece summarizes Rapid Micro Biosystems’ Q3 results versus analyst consensus and notes recent stock underperformance.

Company-level read

Ticker impact

$RPIDBearishHigh confidence
Context

Rapid Micro Biosystems reported Q3 EPS of -0.23, missing by 0.03, and revenue of $9.53M below the $9.8M consensus.

Expected impact

Likely downward pressure as the market digests the EPS and revenue shortfalls versus consensus.

Evidence & confidence

The article provides the company’s own quarterly EPS and revenue versus consensus, which are direct drivers of post-earnings repricing.

Market effects

Limited read-through beyond biotech/life-science tools given the company-specific miss and microcap scale.

No clear regional spillover indicated; move is company-specific.

No global macro or cross-border catalyst mentioned.

Counterpoint

If the miss is driven by timing of revenue recognition rather than underlying demand, the stock could stabilize after initial repricing.

Key entities

  • Rapid Micro Biosystems

    NASDAQ-listed company reporting Q3 EPS and revenue versus consensus.

Related articles

$RPIDHigh

Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results • Reports third quarter 2026 total revenue of $9.5 million, representing 22% growth compared to the third quarter of 2025 ◦ Placed 7 Growth Direct systems and completed 12 validations in the third qu

$MRKMedAI 8/10

Merck KGaA, Darmstadt, Germany Signs Definitive Agreement to Acquire Rapid Micro Biosystems, Advancing Automation in Pharmaceutical Quality Control

Merck KGaA (Germany) agreed to acquire Rapid Micro Biosystems (Nasdaq: RPID) for $0.75 per share. The deal aims to enhance Merck's quality-control workflows with Rapid Micro's automated microbial testing platform, Growth Direct. The acquisition is expected to close in December 2026, subject to regulatory approvals and shareholder tender.